Table 1

Characteristics of sarcoma lines

SarcomaChemosensitivity T/Ca (%) and expression of markers for MDR in xenotransplanted sarcomas
MDR drugsNon-MDR drugsP-glycoprotein, LRP, MRP,b and mdr1-mRNA
No.SubtypeTNM/GradingLesionDoMiViIfPtBlC219JSB1mdr-AB1LRP-56MRP-m6mdr1 mRNA
4013Synovial sarcomaT2N0M1 G3Lung metastasis24c799611c5834
4126ChondrosarcomaT2N0M0 G2Primary3010431c1458861++++++++++
4149MFHT2N0M0 G2Local relapse169107998537133+++++++++
4183RhabdomyosarcomaT2N0M1 G3Primary14c33c998c7629
4254Malignant schwannomaT2N1M1 G3Primary133538428811748
4290ChondrosarcomaT2N0M1 G3Primary662962266990NDNDNDND+
4420Malignant schwannomaT2N0M0 G2Local relapse39c563328c10738cNDND
4448LiposarcomaT2N0M0 G2Local relapse10c21c39633311c
4561Synovial sarcomaT2N0M0 G3Lung metastasis13c27c656617217c++
4605OsteosarcomaT2N0M0 G3Lung metastasis21c110467c1512c
4618LiposarcomaT1N0M0 G3Local relapse332485317127108+
4679LeiomyosarcomaT2N0M0 G3Primary16984887053100+++++
4809MFHT2N0M0 G3Primary17c8039c4233c61++
4917MFHT2N0M0 G3Local relapse4838c17c24c5820c
  • a T/C, tumor volume treated group/tumor volume control group × 100%; Do, doxorubicin; Mi, mitoxantrone; Vi, vincristine; If, ifosfamide; Pt, cisplatin; Bl, bleomycin; MFH, malignant fibrocytic histiocytoma; ND, not done.

  • b −, negative; +, 25% positive; ++, >50% positive cells.

  • c Significant reduction of tumor growth in treated group compared with the control.